Syncom Formulations (India) Past Earnings Performance
Past criteria checks 5/6
Syncom Formulations (India) has been growing earnings at an average annual rate of 9.4%, while the Pharmaceuticals industry saw earnings growing at 13.4% annually. Revenues have been growing at an average rate of 4.5% per year. Syncom Formulations (India)'s return on equity is 9.9%, and it has net margins of 9.8%.
Key information
9.4%
Earnings growth rate
8.7%
EPS growth rate
| Pharmaceuticals Industry Growth | 17.5% |
| Revenue growth rate | 4.5% |
| Return on equity | 9.9% |
| Net Margin | 9.8% |
| Next Earnings Update | 11 Nov 2024 |
Recent past performance updates
Recent updates
Revenue & Expenses Breakdown
How Syncom Formulations (India) makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Jun 24 | 2,908 | 286 | 371 | 0 |
| 31 Mar 24 | 2,634 | 253 | 379 | 0 |
| 31 Dec 23 | 2,498 | 264 | 365 | 0 |
| 30 Sep 23 | 2,420 | 235 | 340 | 0 |
| 30 Jun 23 | 2,327 | 206 | 285 | 0 |
| 31 Mar 23 | 2,243 | 201 | 288 | 0 |
| 31 Dec 22 | 2,215 | 164 | 263 | 0 |
| 30 Sep 22 | 2,213 | 162 | 250 | 0 |
| 30 Jun 22 | 2,198 | 183 | 222 | 0 |
| 31 Mar 22 | 2,197 | 198 | 237 | 0 |
| 31 Dec 21 | 2,270 | 220 | 240 | 0 |
| 30 Sep 21 | 2,539 | 280 | 230 | 0 |
| 30 Jun 21 | 2,668 | 316 | 212 | 0 |
| 31 Mar 21 | 2,448 | 292 | 206 | 0 |
| 31 Dec 20 | 2,223 | 257 | 182 | 0 |
| 30 Sep 20 | 1,905 | 192 | 171 | 0 |
| 30 Jun 20 | 1,809 | 143 | 158 | 0 |
| 31 Mar 20 | 2,055 | 143 | 177 | 0 |
| 31 Dec 19 | 2,237 | 130 | 181 | 0 |
| 30 Sep 19 | 2,191 | 133 | 181 | 0 |
| 30 Jun 19 | 2,077 | 120 | 159 | 0 |
| 31 Mar 19 | 1,868 | 111 | 174 | 0 |
| 31 Dec 18 | 1,648 | 106 | 173 | 0 |
| 30 Sep 18 | 1,566 | 97 | 171 | 0 |
| 30 Jun 18 | 1,505 | 87 | 151 | 0 |
| 31 Mar 18 | 1,586 | 86 | 171 | 0 |
| 31 Mar 17 | 1,848 | 105 | 164 | 0 |
| 31 Mar 16 | 1,839 | 104 | 149 | 0 |
| 31 Mar 15 | 1,734 | 98 | 168 | 0 |
| 31 Mar 14 | 1,513 | 93 | 299 | 0 |
| 31 Dec 13 | 1,429 | 78 | 254 | 0 |
Quality Earnings: 524470 has high quality earnings.
Growing Profit Margin: 524470's current net profit margins (9.8%) are higher than last year (8.9%).
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: 524470's earnings have grown by 9.4% per year over the past 5 years.
Accelerating Growth: 524470's earnings growth over the past year (38.6%) exceeds its 5-year average (9.4% per year).
Earnings vs Industry: 524470 earnings growth over the past year (38.6%) exceeded the Pharmaceuticals industry 19.1%.
Return on Equity
High ROE: 524470's Return on Equity (9.9%) is considered low.